Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Melanoma Treatment
100%
Selective Inhibitor
100%
Catenin
100%
Glycogen Synthase Kinase 3 (GSK3)
100%
Melanoma Cells
42%
IC50
28%
Gene Expression
14%
Knockdown
14%
Small Molecule Inhibitors
14%
Cell Proliferation
14%
Apoptosis
14%
Responsive Genes
14%
Short Hairpin RNA (shRNA)
14%
PARP Cleavage
14%
N-Ras
14%
Human Melanoma Cells
14%
Melanoma Patients
14%
Cytotoxicity Assay
14%
Acquired Resistance
14%
B-Raf
14%
Repeated Dose
14%
Vemurafenib
14%
Melanoma Progression
14%
Caspase Activation
14%
Pathway Activation
14%
GSK-3 Inhibitors
14%
Tumor Growth Delay
14%
BRAF Inhibitor (BRAFi)
14%
Medicine and Dentistry
Catenin
100%
Glycogen Synthase Kinase 3
100%
Melanoma
100%
Melanoma Cell Line
42%
IC50
28%
In Vitro
14%
Gene Expression
14%
Flushing
14%
Cell Line
14%
Tumor Progression
14%
Solid Malignant Neoplasm
14%
Single Drug Dose
14%
Cell Proliferation
14%
Programmed Cell Death
14%
Short Hairpin RNA
14%
Xenograft
14%
Cytotoxicity Assay
14%
Caspase
14%
Poly ADP Ribose Polymerase
14%
Vemurafenib
14%
Tumor Cell Line
14%
Biochemistry, Genetics and Molecular Biology
Catenin
100%
Glycogen Synthase Kinase 3
100%
IC50
28%
Small Molecule
14%
Gene Expression
14%
Flushing
14%
Isoform
14%
Cell Proliferation
14%
Tumor Progression
14%
Small Hairpin RNA
14%
Single Drug Dose
14%
Poly ADP Ribose Polymerase
14%
Caspase
14%
Vemurafenib
14%
Cytotoxicity Assay
14%
Programmed Cell Death
14%
Immunology and Microbiology
Catenin
100%
Melanoma Cell Line
42%
IC50
28%
Cell Line
14%
Flushing
14%
Gene Expression
14%
Cell Proliferation
14%
Tumor Cell Line
14%
Caspase
14%
Cytotoxicity
14%
Xenograft
14%
Programmed Cell Death
14%